Company Overview - Q32 Bio Inc. is a clinical stage biotechnology company focused on developing biologic therapeutics aimed at restoring immune homeostasis in autoimmune and inflammatory diseases [3][4] - The company is developing therapies that target potent regulators of both innate and adaptive immune systems [3] Key Programs - Q32 Bio's lead program, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody currently in a Phase 2 program, designed to re-regulate adaptive immune function for treating autoimmune diseases [4] - The company is also evaluating ADX-097, a program for innate immunity, in a Phase 2 program, which utilizes a novel platform for tissue-targeted regulation of the complement system [4] Upcoming Events - Management will participate in a virtual presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. E.T. [1] - A webcast of the presentation will be available on Q32 Bio's website, with archived replays accessible for 90 days post-event [2]
Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference